ArticleCureus2025
Reducing Delays in Aortic Stenosis Treatment: A Clinical Audit of the Transcatheter Aortic Valve Implantation (TAVI) Pathway and Quality Improvement Initiatives.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Severe aortic stenosis (AS) is a prevalent and life-threatening condition in older adults. Timely valve replacement, either surgical or transcatheter, significantly improves survival. This audit evaluated our transcatheter aortic valve implantation (TAVI) pathway to identify delays and implement targeted quality improvements. Methods A retrospective audit of 29 consecutive patients with severe symptomatic AS referred for TAVI at a tertiary cardiac centre was conducted. Data on three key intervals, namely, referral-to-clinic, clinic-to-multidisciplinary team (MDT) decision, and MDT-to-procedure, were extracted from hospital records. Compliance with predefined timing targets (≤6 weeks per interval, ≤18 weeks total) was assessed, along with wait-list and 30-day mortality. Descriptive statistics summarized waiting times and compliance rates. Results The mean age was 76.3±9.8 with a median of 79; 18 (62%) were male, and 25 (86%) presented in New York Heart Association (NYHA) class III/IV heart failure. The mean total referral-to-TAVI time was 155±24 days (median 155), exceeding the 126-day benchmark; only three (10%) received treatment within 18 weeks. Referral-to-clinic targets were largely met in 23 (79%) patients, but major delays occurred between clinic and MDT (mean 56 days) and MDT-to-procedure (mean 64 days). Two (6.9%) patients died while awaiting TAVI, and among the 27 who underwent TAVI, one (3.7%) died within 30 days. Conclusions This audit revealed substantial delays in the TAVI pathway, primarily due to diagnostic and scheduling bottlenecks, resulting in prolonged waiting times and avoidable adverse outcomes. A quality improvement action plan, including a rapid-access valve clinic, one-stop investigations, increased procedural capacity, and active wait-list monitoring, has been implemented. Re-audit will evaluate the impact on reducing waiting times and improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.